Document Detail

Abnormal growth in noonan syndrome: the challenge of optimal therapy.
MedLine Citation:
PMID:  19550387     Owner:  NLM     Status:  MEDLINE    
Noonan syndrome (NS) is a phenotypically heterogeneous condition frequently associated with short stature. Genetic investigations have identified mutations in several genes, e.g. PTPN11, KRAS, RAF and SOS1 in patients with the NS phenotype and related disorders such as LEOPARD, Costello and Cardiofacio- cutaneous syndromes. In NS, PTPN11 mutations are present in 29-60% of cases. The degree of short stature does not associate closely with the presence of a mutation; however, some PTPN11-positive patients have decreased growth hormone (GH)-dependent growth factors consistent with mild GH insensitivity. GH therapy induces short-term increases in height velocity over 1-3 years, and is likely to improve adult height.
Martin O Savage; Raja Padidela; Jeremy M W Kirk; Alexsandra C Malaquias; Alexander A L Jorge
Related Documents :
18349467 - Goitre and hearing impairment in a patient with pendred syndrome.
12395297 - Duane radial ray syndrome (okihiro syndrome) maps to 20q13 and results from mutations i...
18648327 - Hydrolethalus syndrome: neuropathology of 21 cases confirmed by hyls1 gene mutation ana...
15507137 - Genomic imprinting and assisted reproduction.
4018107 - Caudal dysplasia and femoral hypoplasia-unusual facies syndrome: different manifestatio...
23522947 - Corneal thickness measured by scheimpflug imaging in children with down syndrome.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pediatric endocrinology reviews : PER     Volume:  6 Suppl 4     ISSN:  1565-4753     ISO Abbreviation:  Pediatr Endocrinol Rev     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-24     Completed Date:  2009-08-13     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  101202124     Medline TA:  Pediatr Endocrinol Rev     Country:  Israel    
Other Details:
Languages:  eng     Pagination:  523-8     Citation Subset:  IM    
Department of Endocrinology, Barts and the London School of Medicine and Dentistry, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Body Height
Growth Disorders / drug therapy*,  etiology*
Heart Defects, Congenital / complications
Human Growth Hormone / therapeutic use*
Mitogen-Activated Protein Kinases / genetics
Noonan Syndrome / complications*,  drug therapy*,  genetics
ras Proteins / genetics
Reg. No./Substance:
12629-01-5/Human Growth Hormone; EC Protein Kinases; EC Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  From paediatric to adult endocrinology care: the challenge of the transition period.
Next Document:  Fibromyalgic syndromes: could growth hormone therapy be beneficial?